Exelixis
EXEL
#1765
Rank
โ‚น1.104 T
Marketcap
โ‚น4,119
Share price
-2.51%
Change (1 day)
35.12%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น253.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น268.90. In 2023 the company made an earnings per share (EPS) of โ‚น60.79 an increase over its 2022 EPS that were of โ‚น53.04.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น253.56
2023โ‚น60.7914.61%
2022โ‚น53.04-22.97%
2021โ‚น68.85100%
2020โ‚น34.43-65.09%
2019โ‚น98.63-53.91%
2018โ‚น214.01333.96%
2017โ‚น49.31-260.61%
2016-โ‚น30.71-58.75%
2015-โ‚น74.44-42.45%
2014-โ‚น129.335.3%
2013-โ‚น122.82

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น1,036 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น126.54-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,333 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น192.15-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น680.20 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น321.94 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น350.60 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น341.48-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น78.16-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA